Clinical trialEPhase 1Active not recruiting
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
- Outcome
- Ongoing
- Phase
- EPhase 1
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- November 2016
- Expected end
- December 2026
- Enrollment
- 27 participants
- Sites
- 1
- Primary outcomes
- Assessment of safe administration of 18F-αvβ6-BP
- Sponsor
- Other
- Results posted
- No
- Last update
- 27 February 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.
Detailed description public domain (ClinicalTrials.gov)
PRIMARY OBJECTIVES: I. To determine the safety, biodistribution and dosimetric properties of 18F-alphavbeta6-binding peptide (BP) in normal tissues and malignancies in cancer patients and correlate concordance with alphavbeta6 expression. OUTLINE: Patients receive 18F-alphavbeta6-BP intravenously (IV) and then undergo positron emission tomography (PET) scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection. After completion of study, patients are followed up for up to 6 months.